{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:30:00Z","timestamp":1771659000779,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s12185-021-03253-0","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T17:27:46Z","timestamp":1635874066000},"page":"208-221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study"],"prefix":"10.1007","volume":"115","author":[{"given":"Yoshinori","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiaki","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Kirito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideho","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki I.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Kada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko M.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Edahiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuto","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1880-9126","authenticated-orcid":false,"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,2]]},"reference":[{"key":"3253_CR1","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1056\/NEJMcp1816082","volume":"381","author":"A Tefferi","year":"2019","unstructured":"Tefferi A, Pardanani A. Essential thrombocythemia. N Engl J Med. 2019;381:2135\u201344.","journal-title":"N Engl J Med"},{"key":"3253_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/ejh.12256","volume":"92","author":"O Moulard","year":"2014","unstructured":"Moulard O, Mehta J, Fryzek J, Olivares R, Iqubal U, Mesa RA. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014;92:289\u201397.","journal-title":"Eur J Haematol"},{"key":"3253_CR3","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/ajh.23690","volume":"89","author":"GJ Titmarsh","year":"2014","unstructured":"Titmarsh GJ, Duncombe AS, McMullin MF, O\u2019Rorke M, Mesa R, De Vocht F, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014;89:581\u20137.","journal-title":"Am J Hematol"},{"key":"3253_CR4","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779\u201390.","journal-title":"N Engl J Med"},{"key":"3253_CR5","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.","journal-title":"PLoS Med"},{"key":"3253_CR6","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","volume":"21","author":"A Pardanani","year":"2007","unstructured":"Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007;21:1960\u20133.","journal-title":"Leukemia"},{"key":"3253_CR7","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379\u201390.","journal-title":"N Engl J Med"},{"key":"3253_CR8","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391\u2013405.","journal-title":"N Engl J Med"},{"key":"3253_CR9","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"3253_CR10","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","volume":"120","author":"F Passamonti","year":"2012","unstructured":"Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012;120:1197\u2013201.","journal-title":"Blood"},{"key":"3253_CR11","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120:5128\u201333.","journal-title":"Blood"},{"key":"3253_CR12","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1038\/bcj.2015.94","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5:e369.","journal-title":"Blood Cancer J"},{"key":"3253_CR13","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1532\/IJH97.06009","volume":"83","author":"K Dan","year":"2006","unstructured":"Dan K, Yamada T, Kimura Y, Usui N, Okamoto S, Sugihara T, et al. Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group. Int J Hematol. 2006;83:443\u20139.","journal-title":"Int J Hematol"},{"key":"3253_CR14","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057\u201369.","journal-title":"Leukemia"},{"key":"3253_CR15","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s12185-018-2428-0","volume":"107","author":"A Kamiunten","year":"2018","unstructured":"Kamiunten A, Shide K, Kameda T, Sekine M, Kubuki Y, Ito M, et al. Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture. Japan Int J Hematol. 2018;107:681\u20138.","journal-title":"Japan Int J Hematol"},{"key":"3253_CR16","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s12185-018-2421-7","volume":"107","author":"K Misawa","year":"2018","unstructured":"Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Shirane S, et al. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. Int J Hematol. 2018;107:673\u201380.","journal-title":"Int J Hematol"},{"key":"3253_CR17","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/ejh.13136","volume":"101","author":"Y Hashimoto","year":"2018","unstructured":"Hashimoto Y, Nakamae H, Tanaka T, Omura H, Horiuchi M, Yoshimura T, et al. Validation of previous prognostic models for thrombosis and exploration of modified models in patients with essential thrombocythemia. Eur J Haematol. 2018;101:508\u201313.","journal-title":"Eur J Haematol"},{"key":"3253_CR18","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s12185-020-02964-0","volume":"112","author":"K Shimoda","year":"2020","unstructured":"Shimoda K, Takahashi N, Kirito K, Iriyama N, Kawaguchi T, Kizaki M. JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)\/myeloproliferative neoplasms (MPN). Int J Hematol. 2020;112:268\u201391.","journal-title":"Int J Hematol"},{"key":"3253_CR19","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937\u201351.","journal-title":"Blood"},{"key":"3253_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"3253_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1023\/A:1008859730818","volume":"10","author":"RJ McNally","year":"1999","unstructured":"McNally RJ, Roman E, Cartwright RA. Leukemias and lymphomas: time trends in the UK, 1984\u201393. Cancer Causes Control. 1999;10(1):35\u201342.","journal-title":"Cancer Causes Control"},{"key":"3253_CR22","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179\u201384.","journal-title":"J Clin Oncol"},{"key":"3253_CR23","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/ejh.13041","volume":"100","author":"T Ochiai","year":"2018","unstructured":"Ochiai T, Yasuda H, Araki M, Misawa K, Morishita S, Nudejima M, et al. The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: a comparison in a large-scale cohort. Eur J Haematol. 2018;100:544\u20139.","journal-title":"Eur J Haematol"},{"key":"3253_CR24","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/ejh.13265","volume":"103","author":"T Ito","year":"2019","unstructured":"Ito T, Hashimoto Y, Tanaka Y, Nakaya A, Fujita S, Satake A, et al. Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-na\u00efve essential thrombocythemia patients in a real-world setting. Eur J Haematol. 2019;103:116\u201323.","journal-title":"Eur J Haematol"},{"key":"3253_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12185-020-02876-z","volume":"112","author":"Y Hashimoto","year":"2020","unstructured":"Hashimoto Y, Ito T, Tanaka Y, Nakaya A, Fujita S, Satake A, et al. Comparison of starting doses of anagrelide as a first-line therapy in patients with cytoreductive therapy-na\u00efve essential thrombocythemia: difference between starting at 0.5 and 1.0 mg\/day. Int J Hematol. 2020;112:33\u201340.","journal-title":"Int J Hematol"},{"key":"3253_CR26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","volume":"94","author":"N Szuber","year":"2019","unstructured":"Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, et al. A3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc. 2019;94:599\u2013610.","journal-title":"Mayo Clin Proc"},{"key":"3253_CR27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/bjh.16380","volume":"189","author":"A Tefferi","year":"2020","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020;189:291\u2013302.","journal-title":"Br J Haematol"},{"key":"3253_CR28","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","volume":"96","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol. 2017;96:1653\u201365.","journal-title":"Ann Hematol"},{"key":"3253_CR29","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1007\/s12325-020-01314-0","volume":"37","author":"C Petruk","year":"2020","unstructured":"Petruk C, Mathias J. The myeloproliferative neoplasm landscape: a patient\u2019s eye view. Adv Ther. 2020;37:2050\u201370.","journal-title":"Adv Ther"},{"key":"3253_CR30","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507\u201313.","journal-title":"Blood"},{"key":"3253_CR31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s11899-020-00588-z","volume":"15","author":"C Galvez","year":"2020","unstructured":"Galvez C, Stein BL. Thrombocytosis and thrombosis: is there really a correlation? Curr Hematol Malig Rep. 2020;15:261\u20137.","journal-title":"Curr Hematol Malig Rep"},{"key":"3253_CR32","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","volume":"117","author":"A Carobbio","year":"2011","unstructured":"Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117:5857\u20139.","journal-title":"Blood"},{"key":"3253_CR33","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/leu.2015.277","volume":"30","author":"D Pietra","year":"2016","unstructured":"Pietra D, Rumi E, Ferretti VV, Di Buduo CA, Milanesi C, Cavalloni C, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2016;30:431\u20138.","journal-title":"Leukemia"},{"key":"3253_CR34","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.6004\/jnccn.2017.0157","volume":"15","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, et al. NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018. J Natl Compr Canc Netw. 2017;15:1193\u2013207.","journal-title":"J Natl Compr Canc Netw"},{"key":"3253_CR35","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00277-021-04431-0","volume":"100","author":"I Kre\u010dak","year":"2021","unstructured":"Kre\u010dak I, Holik H, Coha B, Peri\u0107 MM, Zekanovi\u0107 I, Kre\u010dak MV, et al. Low-density lipoprotein (LDL) and the risk of thrombotic events in essential thrombocythemia and polycythemia vera. Ann Hematol. 2021;100:1335\u20136.","journal-title":"Ann Hematol"},{"key":"3253_CR36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.thromres.2018.04.027","volume":"167","author":"A Duan","year":"2018","unstructured":"Duan A, Jackson Chornenki NL, Hillis CM, Gupta V, Anand SS, Siegal DM, et al. Antiplatelet use in patients with essential thrombocythemia: a survey of opinion and Canadian practice. Thromb Res. 2018;167:6\u20138.","journal-title":"Thromb Res"},{"key":"3253_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1600-0609.2009.01246.x","volume":"83","author":"N Gangat","year":"2009","unstructured":"Gangat N, Tefferi A, Thanarajasingam G, Patnaik M, Schwager S, Ketterling R, et al. Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. Eur J Haematol. 2009;83:17\u201321.","journal-title":"Eur J Haematol"},{"key":"3253_CR38","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1365-2141.2011.08858.x","volume":"156","author":"F Palandri","year":"2012","unstructured":"Palandri F, Polverelli N, Catani L, Sollazzo D, Ottaviani E, Parisi S, et al. Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients. Br J Haematol. 2012;156:281\u20134.","journal-title":"Br J Haematol"},{"key":"3253_CR39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","volume":"9","author":"A Kaifie","year":"2016","unstructured":"Kaifie A, Kirschner M, Wolf D, Maintz C, H\u00e4nel M, Gattermann N, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol. 2016;9:18.","journal-title":"J Hematol Oncol"},{"key":"3253_CR40","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/ejh.12064","volume":"90","author":"YS Chou","year":"2013","unstructured":"Chou YS, Gau JP, Yu YB, Pai JT, Hsiao LT, Liu JH, et al. Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage. Eur J Haematol. 2013;90:228\u201336.","journal-title":"Eur J Haematol"},{"key":"3253_CR41","doi-asserted-by":"publisher","first-page":"E93","DOI":"10.1002\/ajh.26114","volume":"96","author":"N Gangat","year":"2021","unstructured":"Gangat N, Szuber N, Jawaid T, Hanson CA, Pardanani A, Tefferi A. Young platelet millionaires with essential thrombocythemia. Am J Hematol. 2021;96:E93\u20135.","journal-title":"Am J Hematol"},{"key":"3253_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa043800","volume":"353","author":"CN Harrison","year":"2005","unstructured":"Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33\u201345.","journal-title":"N Engl J Med"},{"key":"3253_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3324\/haematol.2017.174672","volume":"103","author":"G Birgeg\u00e5rd","year":"2018","unstructured":"Birgeg\u00e5rd G, Besses C, Griesshammer M, Gugliotta L, Harrison CN, Hamdani M, et al. Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the evaluation of anagrelide efficacy and long-term safety study. Haematologica. 2018;103:51\u201360.","journal-title":"Haematologica"},{"key":"3253_CR44","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/ejh.13561","volume":"106","author":"MM P\u00e9rez Encinas","year":"2021","unstructured":"P\u00e9rez Encinas MM, Sobas M, G\u00f3mez-Casares MT, Abuin Blanco A, Noya Pereira MS, Raya JM, et al. The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: a multicentre collaborative study. Eur J Haematol. 2021;106:371\u20139.","journal-title":"Eur J Haematol"},{"key":"3253_CR45","doi-asserted-by":"publisher","first-page":"106495","DOI":"10.1016\/j.leukres.2020.106495","volume":"100","author":"VFI Sangiorgio","year":"2021","unstructured":"Sangiorgio VFI, Nam A, Chen Z, Orazi A, Tam W. GATA1\u00a0downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms. Leuk Res. 2021;100:106495.","journal-title":"Leuk Res"},{"key":"3253_CR46","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/s41375-019-0487-8","volume":"33","author":"T Barbui","year":"2019","unstructured":"Barbui T, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, et al. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case\u2013control study. Leukemia. 2019;33:1996\u20132005.","journal-title":"Leukemia"},{"key":"3253_CR47","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1182\/blood.2019002614","volume":"135","author":"V De Stefano","year":"2020","unstructured":"De Stefano V, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, et al. Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case\u2013control study. Blood. 2020;135:381\u20136.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03253-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-021-03253-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03253-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T19:51:20Z","timestamp":1675885880000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-021-03253-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["3253"],"URL":"https:\/\/doi.org\/10.1007\/s12185-021-03253-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,2]]},"assertion":[{"value":"14 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yoshinori Hashimoto reports honoraria from Takeda Pharmaceutical, research funds under contract from Meiji Seika Pharma, and an endowed chair funded by PharmaEssentia Japan K.K. Tomoki Ito reports honoraria from Novartis Pharmaceutical, Sanofi, and Takeda Pharmaceutical, and honoraria and grants from Abbvie Inc. and Bristol-Meyer Squib. Akihiko Gotoh reports honoraria from Alexion Pharma and Novartis Pharmaceutical, and grants from Chugai Pharmaceutical, Eisai Pharmaceutical, Nippon Shinyaku Pharmaceutical, Ono Pharmaceutical, Taiho Pharmaceutical, and Takeda Pharmaceutical. Mika Nakamae reports honoraria from Novartis Pharmaceutical. Fumihiko Kimura reports grants from Ono Pharmaceutical and Takeda Pharmaceutical. Keita Kirito reports honoraria from Novartis Pharmaceutical. Hideho Wada reports grants from Chugai Pharmaceutical, Kyowa-Hakko Kirin, Ono Pharmaceutical, and Takeda Pharmaceutical. Kensuke Usuki reports research funds under contract from Abbvie Inc., Amgen Astellas BioPharma, Apellis Pharmaceutical, Astellas Pharma, Bristol-Meyer Squib, Daiichi Sankyo, Janssen Pharmaceutical, Nippon Shinyaku Pharmaceutical, Otsuka Pharmaceutical, SymBio Pharmaceutical, and Takeda Pharmaceutical, and honoraria and research funds under contract from Novartis Pharmaceutical. Takehiko Mori reports honoraria from Pfizer, and research funds under contract from Asahi Kasei Pharma, Chugai Pharmaceutical, Kyowa-Hakko Kirin, and Otsuka Pharmaceutical. Kazuya Shimoda reports honoraria from Bristol-Meyer Squib, Celgene, Novartis Pharmaceutical, and Takeda Pharmaceutical, research funds under contract from PharmaEssentia Japan K.K., and grants from Abbvie Inc., Astellas Pharma, Chugai Pharmaceutical, Kyowa-Hakko Kirin, and MSD. Yuka\u00a0Sugimoto reports honoraria from Novartis Pharmaceutical, research funds under contract from Takara Bio Inc., grants from Astellas Pharma, Kyowa-Hakko Kirin, and Ono Pharmaceutical, and an endowed chair funded by Shojunkai Takeuchi Hospital. Akihiro Tomita reports honoraria from Takeda Pharmaceutical, research funds under contract from Kyowa-Hakko Kirin, Novartis Pharmaceutical, Ono Pharmaceutical, Perseus Proteomics\u00a0Inc., Pfizer, and Taiho Pharmaceutical, and honoraria and research funds under contract from Chugai Pharmaceutical. Yoko Edahiro reports research funds under contract from Meiji Seika Pharma, and an endowed chair funded by PharmaEssentia Japan K.K. Koichi Akashi reports honoraria from Celgene and Novartis Pharmaceutical, grants from Asahi Kasei Pharma, Mochida, MSD, Mundi Pharma, Nippon Shinyaku Pharmaceutical, Ono Pharmaceutical, Shionogi, Sanofi, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Toyama Chemical, Shin Nippon Biomedical Laboratories, Yakult Honsha, and Takeda Pharmaceutical, honoraria and research funds under contract from Bristol-Meyer Squib and Janssen Pharmaceutical, honoraria and grants from Abbvie Inc., Chugai Pharmaceutical, and Eisai Pharmaceutical, research funds under contract and grants from Daiichi Sankyo and Otsuka Pharmaceutical, honoraria, research funds under contract, and grants from Astellas Pharma and Kyowa-Hakko Kirin. Itaru Matsumura reports honoraria from Amgen Astellas BioPharma, Bristol-Meyer Squib, Daiichi Sankyo, and Janssen Pharmaceutical, research funds under contract from Alexion Pharma, grants from Kyowa-Hakko Kirin, Mitsubishi Tanabe Pharma, MSD, Nippon Shinyaku Pharmaceutical, Ono Pharmaceutical, Sanofi, Shionogi, Sumitomo Dainippon Pharma, and Taiho Pharmaceutical, honoraria and research funds under contract from Pfizer, honoraria and grants from Astellas Pharma and Otsuka Pharmaceutical, research funds under contract and grants from Chugai Pharmaceutical, Eisai Pharmaceutical, and Takeda Pharmaceutical, honoraria, research funds under contract, and grants from Abbvie Inc. and Novartis Pharmaceutical. Katsuto Takenaka reports honoraria from Novartis Pharmaceutical and MSD, grants from Astellas Pharma, Chugai Pharmaceutical, and Otsuka Pharmaceutical, and honoraria and grants from Kyowa-Hakko Kirin. Norio Komatsu reports honoraria from Abbvie Inc., Celgene, and Japan Tobacco Inc., research funds under contract from FUJIFILM Wako Chemicals, Fuso-pharm, Meiji Seika Pharma, Perseus Proteomics\u00a0Inc., and Pfizer, grants from Bristol-Meyer Squib, Chugai Pharmaceutical, Kyowa-Hakko Kirin, and Sumitomo Dainippon Pharma, honoraria and grants from Novartis Pharmaceutical and Otsuka Pharmaceutical, honoraria, research funds under contract, and grants from Takeda Pharmaceutical, honoraria, research funds under contract, and an endowed chair funded by PharmaEssentia Japan K.K. The other authors declare that they have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}